| Date Filed | Type | Description |
| 09/27/2023 |
8-K
| Quarterly results |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 07/27/2023 |
8-K/A
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 07/24/2023 |
8-K
| Quarterly results |
| 07/20/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 07/19/2023 |
8-K
| Quarterly results |
| 07/11/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 07/07/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 07/07/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 07/05/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 07/05/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 06/07/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/15/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 05/01/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 05/01/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
8-K
| Quarterly results |
| 04/25/2023 |
8-K
| Quarterly results |
| 04/06/2023 |
SC 13G
| BlackRock Inc. reports a 4.9% stake in VBI Vaccines Inc |
| 04/04/2023 |
8-K
| Material Modifications to Rights of Security Holders, Departure of Directors or Certain Officers; Election of Directors; Appo...|
Docs:
|
"EMPLOYMENT AGREEMENT This Employment Agreement is made as of April 3, 2023 by and between Nell Beattie, on the one hand , and VBI Vaccines Inc., a Delaware corporation , on the other hand. WHEREAS, the Executive has been an Executive and an Officer of the Company, as Chief Business Officer, since September 21, 2017 ; and WHEREAS, the Executive will assume a new role and title of Chief Financial Officer and Head of Corporate Development effective April 10, 2023; and WHEREAS, the Company and the Executive desire to set forth, in a definitive employment agreement, their respective rights and obligations with respect to the Executive’ s employment by the Company; and WHEREAS, the Executive is a key employee of the Company with significant access to information concerning the Company, its subsi...",
"VBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock Split" |
|
| 03/13/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/13/2023 |
8-K
| Quarterly results |
| 02/28/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 12/30/2022 |
8-K
| Quarterly results |
| 12/27/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 12/08/2022 |
8-K
| Quarterly results |
| 12/06/2022 |
8-K
| Quarterly results |
| 11/22/2022 |
8-K
| Quarterly results |
| 11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/10/2022 |
8-K
| Quarterly results |
| 10/20/2022 |
8-K
| Quarterly results |
| 10/12/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
|